Abstract: The present disclosure relates to an angstrom silver injection for a cancer inhibition, a preparation method and an application. A composition of the angstrom silver injection includes: angstrom-level elementary substance silver powder with a concentration between 0.005 g/L and 0.500 g/L, medicinal anhydrous fructose with a concentration between 0.5 g/L and 1.0 g/L; sterile distilled water with a. concentration between 998.500 g/L and 999.495 g/L. Tumor cell membrane surface has higher negative charge, and the increase of the negative charge on the membrane surface relates to acid mucopolysaccharide, DNA, and side chain charge of protein, especially to the increase or exposure of sialic acid. Angstrom silver and silver ions have positive charge to combine with the protein and nucleic acid molecule with negative charge inside and outside cells for interfering with synthesis of the protein and replication and transcription of the DNA to destroy normal life activity of cancerous cells.
Type:
Application
Filed:
June 20, 2018
Publication date:
February 6, 2020
Inventors:
Weiyi Situ, Hui Xie, Yang Wang, Rong Fan
Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
Type:
Application
Filed:
October 16, 2017
Publication date:
February 6, 2020
Applicants:
CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON
Abstract: Provided herein are ST-?DC1 and populations of those cells, methods for making ST-?DC1 and populations of those cells, and methods for using ST-?DC1 and populations of those cells for the treatment of cancer, precancerous conditions and chronic infections.
Abstract: Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
Type:
Application
Filed:
August 1, 2019
Publication date:
February 6, 2020
Inventors:
Hans G. Klingemann, Laurent H. Boissel, John H. Lee, Nathan T. Schumer
Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to administration to the patient.
Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes and relates to administering a genetically modified T cell to express a CAR system wherein the CAR system comprises a polynucleotide encoding multiple signaling-modules with either multiple antibody targeting tumor specific antigen or with membrane bound cytokine to further enhance immune cell survival and proliferation. The multi-costimulatory signaling structure gave less toxicity than conventional CAR-T structures using CD28 signaling domain. A CAR system with multiple antibodies targeting different tumor specific antigen can target difference cancer cell populations simultaneously.
Abstract: The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
Type:
Application
Filed:
August 12, 2019
Publication date:
February 6, 2020
Inventors:
Christopher Walter ALMA, Jeffrey BARTLETT, Louis Randall BRETON, Geoffrey Phillip SYMONDS, Ming YAN
Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
October 21, 2019
Publication date:
February 6, 2020
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
October 21, 2019
Publication date:
February 6, 2020
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
October 21, 2019
Publication date:
February 6, 2020
Inventors:
Heiko SCHUSTER, Franziska HOFFGAARD, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Daniel Johannes KOWALEWSKI, Chih-Chiang TSOU
Abstract: Compositions and methods for the prevention and/or treatment of conditions involving disease or damage in mammalian cartilage and bone, using mesenchymal stem cells isolated with anti-integrin ?10 antibodies are disclosed.
Type:
Application
Filed:
July 23, 2019
Publication date:
February 6, 2020
Applicant:
Xintela AB
Inventors:
Evy Lundgren Åkerlund, Christina Uvebrant, Jan Talts
Abstract: Provided herein are compositions and methods for healing cartilage tissue defects or injury by forming fibrochondrocyte cells or fibrochondrocyte-like cells from recruited progenitor cells, such as mesenchymal stem cells.
Abstract: The present invention relates to the field of premature birth. More specifically, the present invention provides methods and compositions useful for preventing premature birth. In one embodiment, a method for preventing preterm birth in a patient comprises the step of administering to the patient an effective amount of autologous mesenchymal stem cells (MSCs) during the first or second trimester.
Type:
Application
Filed:
October 1, 2019
Publication date:
February 6, 2020
Inventors:
Irina Burd, Karin Blakemore, Michael V. Johnston, Ali S. Fatemi
Abstract: The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.
Type:
Application
Filed:
October 11, 2019
Publication date:
February 6, 2020
Inventors:
Alfredo Quinones-Hinojosa, Jordan Green
Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
Type:
Application
Filed:
April 29, 2019
Publication date:
February 6, 2020
Inventors:
Alexander J. Annala, Karen Aboody, Jennifer Covello, Rachael Mooney
Abstract: Methods and compositions comprising a biomaterial that are useful for treating a subject with a condition are described. More specifically, methods of treating a subject with a cardiovascular condition comprising delivering a biomaterial comprising extracellular matrix, and delivering a therapeutic cardiac device or therapeutic agents to the subject are described. In addition, methods of delivering extracellular matrix to a subject are also described.
Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating recurrent diverticulitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
Abstract: The present disclosure provides compositions and methods for treating demyelinating conditions. More particularly, the present disclosure relates to compositions including DUOC-01 cell product and an anti-inflammatory agent; methods for preparing such compositions; and methods of using such compositions in combination or in conjunction with each other for treatment of treating demyelinating conditions.
Type:
Application
Filed:
July 12, 2019
Publication date:
February 6, 2020
Inventors:
Joanne Kurtzberg, Andrew E. Balber, Arjun Saha, Pamela Noldner, Paula Scotland
Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.
Abstract: Probiotic compositions, particularly oral compositions, comprising one or more bacteria that are capable of producing nitrite and/or nitric oxide in a subject are provided. Some compositions further comprise nitrate/nitrate, such as a botanical source of nitrate. Some compositions further comprise botanical sources of nitrate reductase. Also, provided are methods of improving the oral and/or vascular health of a subject by orally administering a composition comprising one or more bacteria capable of producing nitric oxide. Methods of repopulating the nitric oxide producing microflora and bacterial environment in the oral cavity of a subject are also provided.
Abstract: The present invention provides a composition for preventing or treating a graft-versus-host disease, the composition comprising a fecal microbiota.
Abstract: An object of the present invention is to provide an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, and a food or drink composition for improving a mental health disfunction which are effective for improving a mental health disfunction, which are highly safe, and which can be continuously ingested on a daily basis, and this object is achieved by an agent for improving a mental health disfunction or a composition for improving a mental health disfunction, or a food or drink composition for improving a mental health disfunction, each comprising as an active ingredient a bacterium belonging to Bifidobacterium longum subsp. infantis.
Type:
Application
Filed:
February 22, 2018
Publication date:
February 6, 2020
Applicant:
MORINAGA MILK INDUSTRY CO., LTD.
Inventors:
Hirosuke Sugahara, Kanetada Shimizu, Toshitaka Odamaki, Yeong Yeh Lee
Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
Abstract: Provided herein are methods and compositions related to nucleic acids encoding ornithine transcarbamylase (OTC), such as nucleic acids comprising an OTC codon-optimized sequence, as well as related vectors, such as AAV vectors. Also, provided are methods for administering AAV vectors that comprise a sequence that encodes an enzyme associated with an urea cycle disorder and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.
Type:
Application
Filed:
July 16, 2019
Publication date:
February 6, 2020
Applicant:
Selecta Biosciences, Inc.
Inventors:
Peter Keller, Takashi Kei Kishimoto, Andres Muro, Giulia De Sabbata
Abstract: Provided herein are methods and compositions related to nucleic acids encoding methylmalonyl-CoA mutase (MUT) as well as related vectors, such as AAV vectors and Anc80 vectors. Also, provided are methods for administering viral vectors that comprise a sequence that encodes an enzyme associated with an organic acidemia and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.
Abstract: Disclosed herein are compositions having standardized potencies for use in the treatment of warts. Methods of treating a common wart comprising administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof are also disclosed. Further disclosed are methods of treating a non-common wart administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof.
Abstract: A method for combining energy supplements such as energy drinks or food items with cannabis extract. The energy supplements include at least one energizing active ingredient of variable potency. The cannabis extract may be produced of variable potency from at least one strain of cannabis. The agglomerated product may be produced in various forms of food or beverages. When used, the agglomerated product may provide the typical effects of cannabis in addition to the added energy and focus provided by energy supplements.
Abstract: Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.
Abstract: Method of isolating natural molecules: ? and ? pyranocycloartobiloxanthone A and Artonine E, from the stem bark of Artocarpus hirsutus and their anti-acne potential by inhibiting the growth of Propionibacterium acnes thereof, are described.
Type:
Application
Filed:
December 22, 2016
Publication date:
February 6, 2020
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam, Mahadeva Nayak, Nagarajan Ananthanarayanan
Abstract: Provided is a composition for reducing the fat content of fat-producing cells and applications thereof. The composition includes plant extracts such as a blueberry extract and a black tea extract.
Abstract: A composition for treating erectile dysfunction in a male mammal comprising an Orchis anatolica root bulb extract. A method of treating erectile dysfunction in a mammal comprises administering a therapeutically effective amount of Orchis anatolica root bulbs alcohol extract in a male mammal.
Abstract: This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phytopharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.
Type:
Application
Filed:
October 10, 2019
Publication date:
February 6, 2020
Inventors:
Rajan DATT, SIDDHARTH PANDEY, PALLAVI SHRIVASTAVA, RAMADHAR KUMAR
Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.
Type:
Application
Filed:
October 23, 2019
Publication date:
February 6, 2020
Inventors:
Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
Type:
Application
Filed:
September 12, 2019
Publication date:
February 6, 2020
Applicants:
Cornell Research Foundation, Inc., Institut De Recherches Cliniques de Montreal
Inventors:
Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.
Type:
Application
Filed:
September 13, 2018
Publication date:
February 6, 2020
Applicant:
ARCH CANCER THERAPEUTICS, INC.
Inventors:
STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
Abstract: The present invention relates to a composition comprising SEQ ID NO:1 or 2 and one or more pharmaceutically acceptable carriers or diluents. The present invention further relates to the use of the composition as defined in claim 1 or SEQ ID NO:1 or 2 for the manufacture of a medicament for the treatment of neurodegenerative diseases. The present invention further relates to a method of treating neurodegenerative diseases.
Abstract: Provided are non-NHE3-binding agents having activity as phosphate transport/uptake inhibitors in the gastrointestinal tract, including in the small intestine, methods for their use as therapeutic or prophylactic agents, and related methods of drug discovery.
Type:
Application
Filed:
July 15, 2019
Publication date:
February 6, 2020
Applicant:
Ardelyx, Inc.
Inventors:
Dominique Charmot, Jason G. Lewis, Jeffrey W. Jacobs, Ingrid Langsetmo, Christopher Carreras
Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.
Type:
Application
Filed:
December 7, 2017
Publication date:
February 6, 2020
Inventors:
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far
Abstract: Provided is a polypeptide having hypoglycemic and hypolipidemic activities, and the use thereof in the manufacture of a medicament for lowering the blood glucose and/or blood lipid level in a mammal, or for preventing and/or treating diabetes and/or hyperlipidemia in a mammal. Also provided is a composition comprising the polypeptide.
Abstract: An object of the present invention is to provide an active ingredient for a wound healing agent that has high biocompatibility and an antimicrobial activity, as well as a wound healing accelerating activity, which can be applied to supply of a wound healing agent comprising a single active ingredient, which can be produced by a simple production process and production apparatus. According to the present invention, at least one compound selected from a protamine and pharmaceutically acceptable salts thereof is used as an active ingredient for antibacterial activity and wound healing acceleration of a wound healing agent.
Abstract: A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.
Type:
Application
Filed:
October 12, 2017
Publication date:
February 6, 2020
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Reconstituted HDL formulations, methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The reconstituted HDL formulations comprise an apo lipoprotein, a lipid, a detergent and a stabilizer such as sucrose. Treatment of MI patients with repeated infusions of rHDL enhance cholesterol efflux capacity and do not produce significant alterations in liver or kidney function. The MI patient may have normal kidney function or moderate renal impairment.
Type:
Application
Filed:
November 10, 2017
Publication date:
February 6, 2020
Applicant:
CSL LIMITED
Inventors:
Samuel Wright, Charles Shear, Denise D'Andrea, Andreas Gille, Danielle Duffy
Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
Type:
Application
Filed:
October 7, 2019
Publication date:
February 6, 2020
Applicant:
Chan Soon-Shiong Nanthealth Foundation
Inventors:
Kayvan NIAZI, Shahrooz RABIZADEH, Justin GOLOVATO, Oleksandr BUZKO, Anne-Laure LE NY, Patrick SOON-SHIONG
Abstract: A material for treatment of brain injury, a method for treatment of brain injury, a material for regeneration of brain neurons, and a method for regeneration of brain neurons are provided. The material for treatment of brain injury contains a carrier on which at least one selected from the group consisting of N-cadherin, a fusion protein containing an entire or partial region of N-cadherin, and a fusion protein containing an entire or partial region of a protein having homology to N-cadherin is immobilized or coated.
Type:
Application
Filed:
June 28, 2019
Publication date:
February 6, 2020
Applicants:
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, SOMAR CORPORATION
Abstract: Bioconjugation methods for promoting wound healing are disclosed. In particular, the invention relates to the in situ application of non-photochemical crosslinking techniques such as copper-free click chemistry using strain-promoted azide-alkyne cycloaddition (SPAAC) or multi-functional succinimidyl esters as a therapeutic delivery modality for biomolecules and stem cells to enhance wound healing.
Type:
Application
Filed:
February 5, 2018
Publication date:
February 6, 2020
Inventors:
David Myung, Gabriella Fernandes-Cunha, Hyung Jong Lee
Abstract: The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced ability, to assemble a functional dystrophin-associated glycoprotein complex (DGC) that results in an inability, or reduced ability, to establish cell polarity. The method includes administering to the patient a sufficient amount of an epidermal growth factor receptor (EGFR) pathway activator to stimulate asymmetric division of at least some satellite stem cells.
Abstract: The present inventors discovered that an HMGB1 fragment peptide having a particular amino acid sequence exhibits effects of inhibiting finger adhesion and digestive tract scarring and prolonging survival in the dystrophic epidermolysis bullosa model mice. Also in the skin ulcer model, administration of the specific HMGB1 fragment peptide was found to inhibit the fibrosing of skin during the healing process of the ulcer. Based on these findings, the present application provides pharmaceutical compositions for the treatment of fibrotic diseases, which comprise the specific HMGB1 fragment peptide.
Abstract: The invention discloses Interferon alpha (IFN-?) messenger-RNA (mRNA), wherein the mRNA has a 5? CAP region, a 5? untranslated region (5?-UTR), a coding region, a 3? untranslated region (3?-UTR) and a poly-adenosine tail (poly-A tail), for use in the prevention and treatment of non-melanoma skin cancer (NMSC) and kits for administrating this IFN-? mRNA to a human patient.
Type:
Application
Filed:
March 29, 2018
Publication date:
February 6, 2020
Inventors:
Markus MANDLER, Achim SCHNEEBERGER, Walter SCHMIDT, Frank MATTNER